



FIGURE 1


a




b



c



d



e




FIGURE 2




FIGURE 3





FIGURE 4

a

Medium

LAC



Percentage of cells in S/G2/M and G1 phases


	Med		LAC	
	S/G2/M	G1	S/G2/M	G1
G2/M (0h)	82.8	17.4		
4h	33.0	67.0	40.2	59.8
8h	41.9	58.1	36.5	63.5

FIGURE 6A

b

Medium

LAC



Percentage of cells in G1 and S/G2/M phases

	Med		LAC	
	G1	S/G2/M	G1	S/G2/M
Non Sync.	45.5	54.5		
G1/S (0h)	75.0	25.0		
3h	48.9	53.1	59.5	40.5
6h	34.4	65.6	43.1	56.9
9h	30.3	69.7	25.2	74.8
12h	42.3	57.7	27.8	72.2
16h	48.9	53.1	30.7	69.3
20h	56.0	44.0	55.7	44.3

BTCTIDE CR

C

FOET 20 12400660

PHA




FIGURE 6C

CD3




FIGURE 5

102120" 13270300

d




FIGURE 6D

FIG. 7





FIGURE 7

a.



b.





FIGURE 8

a.



b.




FIGURE 9

**Lactacystin inhibits aggregation of
PHA-stimulated human PBMC**




FIGURE 10

09504251.074204
F02T2015240560

**Lactacystin inhibits aggregation of
mitogen-stimulated mouse lymph node cells**




FIGURE 11

1




FIGURE 12




FIGURE 13




FIGURE 14

FIGURE 15




FIGURE 16





FIGURE 17






FIGURE 18




FIGURE 19

FIGURE 19

FIGURE 20




FIGURE 20

Eliminating Alloantigen-specific Response by a Proteasome Inhibitor




Fig. 21

Z-VAD.fmk blocks Lactacystin induced apoptosis in Jurkat cell




Fig. 22




Fig. 23

DNA-fragmentation in Namalwa-Control (▨) and Namalwa-BclX_L (■) cells during Lactacystin (LAC) induced apoptosis.




Fig. 24





Fig. 25

DIPEPTIDE BORONIC ACID (DPBA)

Pyz-Phe-boroLeu; Pyz, 2,5-pyrazinecarboxylic acid



LACTACYSTIN




FIGURE 26

0904251-074204

DPBA INHIBITS 20S PROTEASOME ACTIVITY




FIGURE 27

Proteasome Inhibitor DPBA Inhibits Anti-CD3 Stimulated T Cell Proliferation





FIGURE 28

Proteasome Inhibitor DPBA Prolongs Mouse Heart Allograft Survival



Groups	Survival Days	MST \pm SD	p value
1 Control	7, 7, 7, 7, 8, 8	7,3 \pm 0.5	—
2 DPBA 0.65mg/kg x 16 days	13, 16, 21 >40, >40, >16	>26.1 \pm 13	0.006
3 DPBA 1.0mg/kg x 4 days, then 0.5mg/kg x 12 days	20, 29, >40 >16, >16 >16	>22.8 \pm 9.8	0.008





FIGURE 29

Proteasome Inhibitor DPBA is Effective in Treating Ongoing Heart Allograft Rejection in Mice



Groups	Survival Days	MST \pm SD	p value
1 Control	7, 7, 7, 7, 8, 8	7,3 \pm 0.5	—
2 DPBA 1.0mg/kg/day i.p. x 4 days	10, >14, >14 >14, >14,	>13.2 \pm 1.78	0.0001




FIGURE 30

Islet Transplantation in the Mouse Model




Figure 31